



Technologies for Influenza Vaccines that Provide Increased Speed, Efficacy and Ease of Administration

Guest Editors:

Dr. Ruben Donis

United States Department of
Health and Human Services,
Washington, DC 20201, USA

Dr. Leah Watson

United States Department,
Health and Human Services,
Washington, DC 20201, USA

Deadline for manuscript
submissions:

closed (30 November 2022)

Message from the Guest Editors

Dear Colleagues,

This Special Issue seeks original contributions on technologies that support the development and licensure of new influenza vaccines that outperform currently licensed vaccines in efficacy, speed, flexibility, and ease of administration. Manuscripts that describe new vaccines that rely on flexible “platform technologies” (e.g., nucleic acid, recombinant proteins, and viral vectors) that shorten the time to develop a pandemic vaccine (from sequence to large-scale manufacture) are of particular interest, especially if they provide increased efficacy and ease of administration relative to current vaccines. Special consideration will be given to manuscripts on technologies to immunize naive populations with a single-dose regimen. Manuscripts that report original research findings on technologies that have demonstrated preclinical efficacy will be prioritized.

This Issue will bring together innovative vaccine technologies for different respiratory viruses that could be integrated and leveraged to develop disruptive vaccines for influenza and other respiratory pathogens with pandemic potential.

Dr. Ruben Donis
Guest Editor





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious
Diseases, College of Veterinary
Medicine, University of Georgia,
Athens, GA 30602-7387, USA

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Author Benefits

Open Access: free for readers, with **article processing charges (APC)** paid by authors or their institutions.

High Visibility: indexed within **Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPus / SciFinder, and other databases.**

Journal Rank: JCR - Q1 (Immunology) / CiteScore - Q1 (Pharmacology (medical))

Contact Us

Vaccines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/vaccines
vaccines@mdpi.com